GSK Acquires RAPT Therapeutics in New Agreement

GSK plc has announced its definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company based in California. This acquisition will include ozureprubart, a monoclonal antibody designed to provide prophylactic protection against food allergens.

Details of the Acquisition

The deal involves an estimated total equity value of $2.2 billion, with GSK paying $58.00 per share to RAPT shareholders. The calculated upfront investment is about $1.9 billion after accounting for cash acquired. GSK plans to acquire the global rights to ozureprubart, excluding specific regions in Asia.

Ozureprubart: A Revolutionary Treatment

Ozureprubart is currently in phase IIb clinical development. It targets immunoglobulin E (IgE), a validated target in immunologic conditions. The antibody could offer patients protection from harmful allergic reactions with an innovative dosing schedule, potentially every 12 weeks.

• Current standard anti-IgE treatments require injections every 2 to 4 weeks.
• Ozureprubart aims to alleviate the burden of frequent dosing, especially in pediatric patients.
• Approximately 25% of patients are ineligible for existing therapies.

Impact of Food Allergies

In the United States, over 17 million people are diagnosed with food allergies, leading to more than 3 million emergency visits each year. Severe reactions affect more than 1.3 million individuals, primarily children and adolescents. These alarming statistics underline the pressing need for innovative therapies like ozureprubart.

Expected Outcomes and Timeline

GSK expects to release data from its phase IIb trial in 2027. The next stages of clinical trials will focus on both adult and pediatric at-risk populations. This acquisition is designed to bolster GSK’s existing pipeline in Respiratory, Immunology, and Inflammation.

Statements from Leadership

GSK’s Chief Scientific Officer, Tony Wood, emphasized the potential of ozureprubart as a best-in-class treatment option. Brian Wong, CEO of RAPT Therapeutics, shared excitement about the partnership, highlighting the access GSK can provide to global resources and capabilities.

Transaction Details

The acquisition transaction remains subject to customary closing conditions. This includes a tender offer for the majority of RAPT’s outstanding shares within 10 business days of the agreement signing. The completion of this acquisition is expected by the first quarter of 2026.

Legal and Financial Advisors

GSK is advised by Evercore on financial matters, with legal counsel from A&O Shearman. RAPT Therapeutics is represented by J.P. Morgan Securities as a financial advisor and Cooley LLP for legal support.

This acquisition represents a pivotal step in addressing the significant unmet needs of patients with food allergies, underscoring GSK’s commitment to advancing innovative healthcare solutions.